CoChat

Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication

Open access
Jehad, Mohammad Abdullah, Ali, Lizna M, Pillai, Vineeta N, Prabhu, Suresha G, Mustafa, Farah, Rizvi, Tahir A · 2026 · FEMS Microbiology Reviews

The DOI matches its Crossref record; 697 of the 697 references it cites were found in a registry or an index; 147 of the 537 sources its claims cite were checked for support.

Abstract

Retroviruses are exclusive group of positive-sense RNA viruses defined by their ability to reverse transcribe their RNA genome and integrate it into the host's chromosomal DNA. This distinctive replication strategy enables persistent infection and has profoundly shaped our understanding of molecular biology, gene regulation, and evolution. Retroviruses have contributed to landmark discoveries, including the identification of oncogenes, mechanisms of transcriptional control, and the development of gene therapy vectors. This review provides an updated overview of retroviral molecular biology, emphasizing the coordinated steps of the viral life cycle and emerging insights that are reshaping classical models. It explores virion structure, genome organization, and the interplay of cis-acting sequences and trans-acting factors that govern replication. Special focus is given to recent advances in understanding nuclear trafficking of capsids, spatial dynamics of reverse transcription and integration leading to provirus formation, RNA nuclear export, and selective genome packaging. The structural and functional roles of viral proteins, particularly Gag, are discussed in the context of assembly and maturation. By integrating foundational concepts with new discoveries, this review highlights the molecular sophistication of retroviral replication and identifies outstanding questions that guide future research, with implications extending to antiviral strategies, gene therapy, cancer biology, and evolution.

Overview

CoChat Summary

TL;DR

This is a review of retroviral replication that synthesizes classical and newer findings on entry, reverse transcription, nuclear import/uncoating, integration, transcription, RNA export, translation, assembly, and maturation. Its main message is that retroviral replication is shaped by tightly coordinated viral and host factors, and newer work is revising long-held ideas about where and when key steps occur.

Key findings

  • Retroviruses reverse transcribe their RNA genome into dsDNA and integrate it into host chromosomal DNA, creating a provirus; the review emphasizes this as the defining replication strategy and notes that transcription occurs only after proviral integration in the prevailing model.
  • The paper highlights newer evidence that challenges older dogma: in HIV-1, reverse transcription begins in the cytoplasm but is completed within the intact capsid in the nucleus, and for MLV the review says a similar cytoplasm-to-nucleus completion has been shown in both dividing and nondividing cells.
  • Retroviral genome expression depends on multiple virus-specific strategies; for example, the review states that HIV-1 uses Tat/TAR, HTLV-1 uses Tax/TRE, and MMTV may have a novel 12-nt cis-acting element that responds to both Tat and Tax.
  • Assembly and packaging are described as highly structured processes: the review states that retroviral particles contain two gRNA copies, Gag drives selective packaging, and HIV-1 assembly depends on a Gag/Pol ratio of 20:1; it also notes that HIV-1 Gag can be sufficient to form noninfectious VLPs and that IP6/IP5 are crucial cofactors for assembly/maturation in HIV-1 and other retroviruses.

Methods

  • Not stated in the paper.
  • The paper is a narrative review that synthesizes published studies across retroviral genera, with figures and tables summarizing retroviral classification, genome organization, and life-cycle steps.
  • Its analysis is integrative and comparative, drawing on prior biochemical, genetic, structural, imaging, and in vitro/in vivo studies rather than presenting a new primary dataset.

Limitations

  • The paper explicitly says there are “outstanding questions” about retroviral biology, including the dynamics of proviral transcriptional regulation, the contribution of host factors, and the timing/location of uncoating and nuclear entry.
  • It also states that the mechanism of entry still “needs to be deciphered molecularly” for many retroviruses, and that for some steps—especially reverse transcription completion and uncoating—the exact location remains unclear for most retroviruses.
  • Because this is a review, it does not report a single study sample or new experiment; this is evident from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/femsre/fuaf066

Cites

697 of 697 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Morphology of core across retroviral genera. Illustration of the distinct mature core morphological types, characteristic of different retroviruses accompanied by representative examples from each group. Figure made in BioRender.com.
Figure 1. Morphology of core across retroviral genera. Illustration of the distinct mature core morphological types, characteristic of different retroviruses accompanied by representative examples from each group. Figure made in BioRender.com.CC BY · PubMed Central
Figure 2. Schematic representation of (a) proviral genome organization across retroviral genera, and (b) a mature retroviral particle showing a dimeric genome inside the core. Representative viruses include: ALV, avian leukosis virus; MMTV, mouse mammary tumor virus; MLV, murine leukemia virus; HTLV-1, human T-lymphotropic virus type 1; WDSV, Walleye dermal sarcoma virus; HIV-1, human immunodeficiency virus type 1; and SFV, simian foamy virus. Black vertical arrows indicate the sites of ribosomal frameshifting within each proviral genome. nts: Nucleotides. Figure made in BioRender.com.
Figure 2. Schematic representation of (a) proviral genome organization across retroviral genera, and (b) a mature retroviral particle showing a dimeric genome inside the core. Representative viruses include: ALV, avian leukosis virus; MMTV, mouse mammary tumor virus; MLV, murine leukemia virus; HTLV-1, human T-lymphotropic virus type 1; WDSV, Walleye dermal sarcoma virus; HIV-1, human immunodeficiency virus type 1; and SFV, simian foamy virus. Black vertical arrows indicate the sites of ribosomal frameshifting within each proviral genome. nts: Nucleotides. Figure made in BioRender.com.CC BY · PubMed Central
Figure 3. Comparison of the retroviral genomic RNA with its proviral DNA integrated into the host genome. Retroviral genome shown as an RNA monomer that is used during reverse transcription to generate a fully double stranded DNA molecule. The reverse transcribed DNA is then integrated into the host chromosomes to form proviral DNA. The figure highlights important cis- and trans-acting features observed in the retroviral genome and needed for reverse transcription, nuclear export, and RNA packaging. Psi (Ψ), Packaging sequences or signals; PBS, primer binding site; PPT, polypurine tract; U5 and U3, sequences unique to the 5′ and 3′ ends of the RNA genome; R, Repeat region; CTE, constitutive transport element; att, attachment sites used during integration; TAR, the trans-activation response element; and RRE, the Rev response element. Figure made in BioRender.com.
Figure 3. Comparison of the retroviral genomic RNA with its proviral DNA integrated into the host genome. Retroviral genome shown as an RNA monomer that is used during reverse transcription to generate a fully double stranded DNA molecule. The reverse transcribed DNA is then integrated into the host chromosomes to form proviral DNA. The figure highlights important cis- and trans-acting features observed in the retroviral genome and needed for reverse transcription, nuclear export, and RNA packaging. Psi (Ψ), Packaging sequences or signals; PBS, primer binding site; PPT, polypurine tract; U5 and U3, sequences unique to the 5′ and 3′ ends of the RNA genome; R, Repeat region; CTE, constitutive transport element; att, attachment sites used during integration; TAR, the trans-activation response element; and RRE, the Rev response element. Figure made in BioRender.com.CC BY · PubMed Central
Figure 4. Illustration of simple and complex retroviral genomes, along with the splicing patterns of their full-length unspliced RNA genome in: (a) murine leukemia virus (MLV), a simple retrovirus, (b) human immunodeficiency virus type 1 (HIV-1), a prototypic complex retrovirus, and (c) MMTV, now recognized as an emerging complex retrovirus. The red circle marks the location of the retroviral promoters. See text for details pertaining to each step. Figure made in BioRender.com.
Figure 4. Illustration of simple and complex retroviral genomes, along with the splicing patterns of their full-length unspliced RNA genome in: (a) murine leukemia virus (MLV), a simple retrovirus, (b) human immunodeficiency virus type 1 (HIV-1), a prototypic complex retrovirus, and (c) MMTV, now recognized as an emerging complex retrovirus. The red circle marks the location of the retroviral promoters. See text for details pertaining to each step. Figure made in BioRender.com.CC BY · PubMed Central
Figure 5. Illustration of a typical retroviral life cycle showing the various stages of retroviral replication. The figure highlights the two modes of assembly observed in different retroviruses, which can occur either directly at the plasma membrane, or in the cytoplasm followed by transport to the plasma membrane where budding virus particles acquire the envelope glycoproteins. See text for details pertaining to each step. Figure made in BioRender.com.
Figure 5. Illustration of a typical retroviral life cycle showing the various stages of retroviral replication. The figure highlights the two modes of assembly observed in different retroviruses, which can occur either directly at the plasma membrane, or in the cytoplasm followed by transport to the plasma membrane where budding virus particles acquire the envelope glycoproteins. See text for details pertaining to each step. Figure made in BioRender.com.CC BY · PubMed Central
Figure 6. Schematic representation of the steps involved in retroviral reverse transcription, beginning with the annealing of a specific host tRNA (depending on the retrovirus) to the PBS on the viral gRNA. −sssDNA and +sssDNA, minus- and plus-strand strong-stop DNA, RT; reverse transcriptase; and PPT, polypurine tract. See text for details pertaining to each step. Figure made in BioRender.com.
Figure 6. Schematic representation of the steps involved in retroviral reverse transcription, beginning with the annealing of a specific host tRNA (depending on the retrovirus) to the PBS on the viral gRNA. −sssDNA and +sssDNA, minus- and plus-strand strong-stop DNA, RT; reverse transcriptase; and PPT, polypurine tract. See text for details pertaining to each step. Figure made in BioRender.com.CC BY · PubMed Central
Figure 7. Illustration of the sequential steps involved in retroviral integration, using MPMV as an example. N, any of the four nucleotides in the host DNA; X and Y, host nucleotides that are six host base pairs away from the inserted viral DNA with 5′ TG and 3′ CA ends. See text for details pertaining to each step. Figure made in BioRender.com.
Figure 7. Illustration of the sequential steps involved in retroviral integration, using MPMV as an example. N, any of the four nucleotides in the host DNA; X and Y, host nucleotides that are six host base pairs away from the inserted viral DNA with 5′ TG and 3′ CA ends. See text for details pertaining to each step. Figure made in BioRender.com.CC BY · PubMed Central
Figure 8. Illustration of the function of (a) Tat/TAR in the transcriptional regulation of human immunodeficiency virus type 1 (HIV-1), compared to the emerging trans-activation system recently identified in the (b) MMTV. See text for details. Figure made in BioRender.com.
Figure 8. Illustration of the function of (a) Tat/TAR in the transcriptional regulation of human immunodeficiency virus type 1 (HIV-1), compared to the emerging trans-activation system recently identified in the (b) MMTV. See text for details. Figure made in BioRender.com.CC BY · PubMed Central
Figure 9. Illustration of the mechanisms used by different retroviruses for the nuclear export of their full-length unspliced RNA. HIV-1, human immunodeficiency virus type 1; HTLV-1, human T-lymphotropic virus type 1; MMTV, mouse mammary tumor virus; CRM1, chromosome region maintenance 1 protein; MPMV, Mason–Pfizer monkey virus; MLV, murine leukemia virus; CTE, constitutive transport element; CAE, cytoplasmic accumulation element; NXF1/TAP, nuclear RNA export factor 1; and HuR, human antigen R. See text for details. Figure made in BioRender.com.
Figure 9. Illustration of the mechanisms used by different retroviruses for the nuclear export of their full-length unspliced RNA. HIV-1, human immunodeficiency virus type 1; HTLV-1, human T-lymphotropic virus type 1; MMTV, mouse mammary tumor virus; CRM1, chromosome region maintenance 1 protein; MPMV, Mason–Pfizer monkey virus; MLV, murine leukemia virus; CTE, constitutive transport element; CAE, cytoplasmic accumulation element; NXF1/TAP, nuclear RNA export factor 1; and HuR, human antigen R. See text for details. Figure made in BioRender.com.CC BY · PubMed Central
Figure 10. Illustration of the ribosomal frameshifting mechanisms employed by different retroviruses to translate overlapping genes from a single start codon (AUG). (a) In feline immunodeficiency virus (FIV) and other lentiviruses, ribosomes undergo a single −1 nt shift (indicated by the green downward arrow) just before the Gag stop codon, altering the reading frame from encoding the Gag precursor protein to the Gag–Pol polyprotein. (b) The MMTV utilizes a more complex mechanism involving two successive −1 frameshifts. The first shift (indicated by the first downward arrow) occurs before the Gag termination codon, switching the reading frame to produce the Gag–Pro polyprotein. A second −1 shift (indicated by the second downward arrow) occurs prior to the Pro stop codon, resulting in translation of the full Gag–Pro–Pol polyprotein. These frameshifting events require a reiterated sequence motif, known as ribosomal frameshift signal (RFS) and a downstream RNA secondary structure, typically a pseudoknot, located 5–8 nts after the frameshift site. See text for details. Figure made in BioRender.com.
Figure 10. Illustration of the ribosomal frameshifting mechanisms employed by different retroviruses to translate overlapping genes from a single start codon (AUG). (a) In feline immunodeficiency virus (FIV) and other lentiviruses, ribosomes undergo a single −1 nt shift (indicated by the green downward arrow) just before the Gag stop codon, altering the reading frame from encoding the Gag precursor protein to the Gag–Pol polyprotein. (b) The MMTV utilizes a more complex mechanism involving two successive −1 frameshifts. The first shift (indicated by the first downward arrow) occurs before the Gag termination codon, switching the reading frame to produce the Gag–Pro polyprotein. A second −1 shift (indicated by the second downward arrow) occurs prior to the Pro stop codon, resulting in translation of the full Gag–Pro–Pol polyprotein. These frameshifting events require a reiterated sequence motif, known as ribosomal frameshift signal (RFS) and a downstream RNA secondary structure, typically a pseudoknot, located 5–8 nts after the frameshift site. See text for details. Figure made in BioRender.com.CC BY · PubMed Central
Figure 11. Illustration of the Gag domain organization in different retroviruses that include MA, CA, and NC. Spacer peptides (SP), other peptides (p or pp followed by a number), and late (L) domain-containing sequences are also shown. HIV/FIV/SIV, human, feline, and simian immunodeficiency viruses; MLV, murine leukemia virus; MMTV, mouse mammary tumor virus; and MPMV, Mason–Pfizer monkey virus. The L domain amino acids are as follows: PTAP: Pro-Thr-Ala-Pro; YPXnL (Tyr-Pro-any amino acid and n = ∼ 1–3 residues-Leu); PSAP: Pro-Ser-Ala-Pro; LXXL: Leu-any amino acid-any amino acid-Leu; PPxY: Pro-Pro-any amino acid-Tyr; and PLPPV: Pro-Leu-Pro-Pro-Val. Figure made in BioRender.com.
Figure 11. Illustration of the Gag domain organization in different retroviruses that include MA, CA, and NC. Spacer peptides (SP), other peptides (p or pp followed by a number), and late (L) domain-containing sequences are also shown. HIV/FIV/SIV, human, feline, and simian immunodeficiency viruses; MLV, murine leukemia virus; MMTV, mouse mammary tumor virus; and MPMV, Mason–Pfizer monkey virus. The L domain amino acids are as follows: PTAP: Pro-Thr-Ala-Pro; YPXnL (Tyr-Pro-any amino acid and n = ∼ 1–3 residues-Leu); PSAP: Pro-Ser-Ala-Pro; LXXL: Leu-any amino acid-any amino acid-Leu; PPxY: Pro-Pro-any amino acid-Tyr; and PLPPV: Pro-Leu-Pro-Pro-Val. Figure made in BioRender.com.CC BY · PubMed Central
Figure 12. A simplistic model of retroviral gRNA packaging based on selective recognition of the viral genome by the structural Gag polyprotein based on the recognition of the higher-order structure of the cis-acting packaging sequences (Psi: ψ). Following transcription from the proviral DNA, unspliced and spliced RNAs are generated which have different fates as illustrated in the figure. Figure made in BioRender.com.
Figure 12. A simplistic model of retroviral gRNA packaging based on selective recognition of the viral genome by the structural Gag polyprotein based on the recognition of the higher-order structure of the cis-acting packaging sequences (Psi: ψ). Following transcription from the proviral DNA, unspliced and spliced RNAs are generated which have different fates as illustrated in the figure. Figure made in BioRender.com.CC BY · PubMed Central
Figure 13. Comparison of an immature retroviral particle shortly after budding (left) and a mature particle (right) following activation of the viral PR. Figure made in BioRender.com.
Figure 13. Comparison of an immature retroviral particle shortly after budding (left) and a mature particle (right) following activation of the viral PR. Figure made in BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

92 Valid · 8 Not valid · 146 Not checked · 44 Own results and interpretations

172 more claims · 57 with their cited sources checked

Create a free account to see all 290 claims and to verify the 130 references still open.

See all claims — free account
  • It may state two separate claims as one. 104
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 7

  1. Brown PO. Integration. In: Coffin JM, Hughes SH, Varmus HE (eds), Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997. 21433344
  2. Coffin JM. Retroviruses. Hughes SH, Coffin JM, Varmus HE (eds). Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997. 21433340
  3. Freed EO, Martin MA. Human immunodeficiency viruses: replication. In: Fields Virology. Vol 2. 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2013, 1502– 60.
  4. Goff SP. Retroviridae. In: Fields Virology. Vol 2. 6th edn. Philadelphia: Lippincott Williams and Wilkins, 2013, 1424– 72.
  5. Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE (eds), Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997. 21433349
  6. Telesnitsky A, Goff SP. Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE (eds), Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997. 21433342
  7. Vogt VM. Retroviral virions and genomes. In: Coffin JM, Hughes SH, Varmus HE (eds), Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997. 21433348

Cited by

See all 5

Metadata

Authors
Jehad, M. A., Ali, L. M., Pillai, V. N., Prabhu, S. G., Mustafa, F., & Rizvi, T. A.
Affiliations
  • United Arab Emirates University (AE)
  • United Arab Emirates University Department of Microbiology and Immunology, College of Medicine and Health Sciences (CMHS), , Al Ain ,
Corresponding author
  • Mustafa, Farah
  • Rizvi, Tahir A
Venue
FEMS Microbiology Reviews
Published
2025-12-26
Volume
50
ISSN
  • 0168-6445 (ISSN-L)
  • 1574-6976
OpenAlex
W7117300912
Cited by
5
References
677
Citations by year
2026: 5
FWCI
0.80
Type
journal article
Language
en
Open access
Locations
  • FEMS Microbiology Reviews (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
  • College of Medicine and Health Sciences, United Arab Emirates University (12M103, 12M215, NP-24-09)
  • United Arab Emirates University (12M136, 12M218, 21M187)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
retroviral replication, reverse transcription, viral integration, viral life cycle, RNA nuclear export, genome packaging, Gag protein, cis-regulatory elements, trans-acting factors, viral oncogenes, gene therapy vectors, antiviral strategies
MeSH terms
Animals, Humans, Retroviridae, Virus Replication, Genome, Viral, Reverse Transcription

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.